Skip to main content

Table 2 Changes of body mass index, skeletal muscle area, and adipose tissue area during the first-line FOLFIRINOX chemotherapy

From: Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients

Variables

Subgroups

Before chemotherapy

After chemotherapy

p-value

Difference (after-before)

Ratio (after/before)

BMI (kg/m2)

Resection (n = 15)

22.7 ± 2.6

22.7 ± 2.8

0.935

0.0 ± 2.2

1.013 ± 0.104

No resection (n = 43)

21.3 ± 3.0

20.6 ± 3.2

0.013

− 0.7 ± 1.7

0.988 ± 0.078

Total (n = 58)

21.7 ± 2.9

21.2 ± 3.2

0.052

− 0.5 ± 1.8

0.997 ± 0.086

SM area (cm2)

Resection (n = 15)

107.4 ± 26.6

107.8 ± 27.3

0.889

0.3 ± 9.2

1.006 ± 0.099

No resection (n = 43)

113.3 ± 24.4

96.2 ± 22.9

 < 0.001

− 17.1 ± 13.6

0.853 ± 0.116

Total (n = 58)

111.8 ± 24.9

99.2 ± 24.4

 < 0.001

− 12.6 ± 14.7

0.911 ± 0.130

AT area (cm2)

Resection (n = 15)

211.4 ± 66.3

214.6 ± 63.4

0.832

3.2 ± 57.0

1.062 ± 0.353

No resection (n = 43)

198.8 ± 91.9

165.2 ± 83.4

 < 0.001

− 33.6 ± 56.8

0.861 ± 0.253

Total (n = 58)

202.1 ± 85.6

178.0 ± 81.2

0.003

− 24.1 ± 58.7

0.889 ± 0.292

  1. The data are presented as mean ± standard deviation
  2. BMI body mass index, SM skeletal muscle, AT adipose tissue